Translation of focused ultrasound for blood-brain barrier opening in glioma

Mar 26, 2022Journal of controlled release : official journal of the Controlled Release Society

Using focused ultrasound to open the blood-brain barrier in brain tumors

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Survival outcomes for patients with glioblastoma multiforme (GBM) have remained poor for the past 15 years.

Systemic therapies for GBM are limited by the blood-brain barrier, which restricts drug delivery to tumor areas.
Focused ultrasound (FUS) may enhance drug delivery by temporarily disrupting the blood-brain barrier.
Current preclinical investigations are exploring FUS as a method to improve therapy effectiveness for intracranial tumors.
Methodological inconsistencies in FUS research could hinder its clinical application.
Selecting relevant animal models and standardizing FUS delivery methods are crucial for future research.

AI simplified

Survival outcomes for patients with glioblastoma multiforme (GBM) have remained poor for the past 15 years, reflecting a clear challenge in the development of more effective treatment strategies. The efficacy of systemic therapies for GBM is greatly limited by the presence of the blood-brain barrier (BBB), which prevents drug penetration and accumulation in regions of infiltrative tumour, as represented in a consistent portion of GBM lesions. Focused ultrasound (FUS) - a technique that uses low-frequency ultrasound waves to induce targeted temporary disruption of the BBB - promises to improve survival outcomes by enhancing drug delivery and accumulation to infiltrating tumour regions. In this review we discuss the current state of preclinical investigations using FUS to enhance delivery of systemic therapies to intracranial neoplasms. We highlight critical methodological inconsistencies that are hampering clinical translation of FUS and we provide guiding principles for future preclinical studies. Particularly, we focus our attention on the importance of the selection of clinically relevant animal models and to the standardization of methods for FUS delivery, which will be paramount to the successful clinical translation of this promising technology for treatment in GBM patients. We also discuss how preclinical FUS research can benefit the development of GBM immunotherapies.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Translation of focused ultrasound for blood-brain barrier opening in glioma

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief